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ABSTRACT
Objective: To identify case definitions for chronic
fatigue syndrome/myalgic encephalomyelitis (CFS/ME),
and explore how the validity of case definitions can be
evaluated in the absence of a reference standard.
Design: Systematic review.
Setting: International.
Participants: A literature search, updated as of
November 2013, led to the identification of 20 case
definitions and inclusion of 38 validation studies.
Primary and secondary outcome measure:
Validation studies were assessed for risk of bias and
categorised according to three validation models:
(1) independent application of several case definitions
on the same population, (2) sequential application of
different case definitions on patients diagnosed
with CFS/ME with one set of diagnostic criteria or
(3) comparison of prevalence estimates from different
case definitions applied on different populations.
Results: A total of 38 studies contributed data of
sufficient quality and consistency for evaluation of
validity, with CDC-1994/Fukuda as the most frequently
applied case definition. No study rigorously assessed
the reproducibility or feasibility of case definitions.
Validation studies were small with methodological
weaknesses and inconsistent results. No empirical data
indicated that any case definition specifically identified
patients with a neuroimmunological condition.
Conclusions: Classification of patients according to
severity and symptom patterns, aiming to predict
prognosis or effectiveness of therapy, seems useful.
Development of further case definitions of CFS/ME
should be given a low priority. Consistency in research
can be achieved by applying diagnostic criteria that
have been subjected to systematic evaluation.
INTRODUCTION
Chronic fatigue syndrome (CFS) is a serious
disorder characterised by persistent postexer-
tional fatigue and substantial symptoms
related to cognitive, immune and autono-
mous dysfunction.1 2 Disease mechanisms
are complex,3 with no single causal factor
identiﬁed. Yet there are indications that
infections4–8 and immunological dysfunc-
tion9 contribute to development and main-
tenance of symptoms, probably interacting
with genetic10 and psychosocial11–13 factors.
Studies have identiﬁed pathological pat-
terns and structures of the central nervous
system,14 15 dysregulation of body tempera-
ture and blood pressure16 17 and dysfunc-
tional stress hormonal systems18 19 in patients
with CFS compared with normal controls.
None of these appears sufﬁciently consistent
to constitute a diagnostic test, and case deﬁ-
nitions (diagnostic criteria) are therefore
used to deﬁne the CFS diagnosis. When case
deﬁnitions are developed, the context of
application must be considered, since differ-
ent properties are needed for case deﬁnition
intended for research purposes compared
with case deﬁnitions used to diagnose indi-
vidual patients. It is also necessary to con-
sider whether a broad (ie, sensitive criteria
ensuring that we do not miss relevant cases)
or narrow (ie, speciﬁc criteria ensuring that
all positive cases are deﬁnite) approach is
most appropriate.
Holmes et al20 coined the term ‘chronic
fatigue syndrome’ in 1988, as an alternative to
‘The chronic Epstein-Barr virus syndrome’.
Since this case deﬁnition—the CDC-1988/
Strengths and limitations of this study
▪ The main strength of our study is the systematic
methods used to identify and appraise articles pre-
senting and evaluating case definitions of chronic
fatigue syndrome/myalgic encephalomyelitis.
▪ We used systematic and transparent approaches
to extract data, categorise the studies according
to prespecified models and to analyse and
compare the data.
▪ The included validation studies showed consider-
able methodological weaknesses and inconsist-
ent results, and it is therefore difficult to draw
firm conclusions.
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Holmes Criteria—was presented in 1988,20 numerous
revisions have been developed, aiming for distinctive and
reliable identiﬁcation of individuals who represent a
homogenous and consistent phenotype of the hypothe-
sised disease entity, consistent with pathophysiological
and psychosocial ﬁndings. Currently, the term ‘myalgic
encephalomyelitis’ (ME) is commonly used to conceptu-
alise a speciﬁc neuroimmunological condition, assumed
to be more severe and less psychologically attributed than
CFS.21 In 2003, Carruthers et al presented the
Canadian-2003 Criteria for diagnosis of ME/CFS.22 A
revised version was presented as International Consensus
Criteria (the ICC-2011 Criteria) for ME,23 claiming to be
a selective case deﬁnition for identiﬁcation of patients
with neuroimmune exhaustion with a pathologically low
threshold of fatigability and symptom ﬂare after exertion.
The assertion that CFS and ME are different clinical
entities is disputed. Below, we will pragmatically apply the
term CFS/ME.
Johnston et al24 conducted a systematic review of the
adoption of CFS/ME case deﬁnitions to assess the preva-
lence and identiﬁed eight different case deﬁnitions.
There is no general agreement on a reference standard
for diagnosis, and no diagnostic test is available. Bossuyt
et al25 include case deﬁnitions in their understanding of
the term ‘test’, emphasising that diagnostic tests are
highly dynamic and need rigorous evaluation before
they are introduced into clinical practice.26
The objectives of our study were to explore strategies
for evaluation of accuracy and concept validity of differ-
ent case deﬁnitions for CFS/ME in the absence of a ref-
erence standard. First, we wanted to conduct a
systematic review to identify and describe different case
deﬁnitions (sets of diagnostic criteria) for CFS/ME.
Second, we wanted to explore differences between
various case deﬁnitions by identifying and reviewing
validation studies.
MATERIALS AND METHODS
Protocol and registration
We developed a protocol for our study. However, we did
not publish or register it.
Eligibility criteria
We included studies presenting or validating case deﬁni-
tions for CFS/ME for adult populations (>18 years). No
language restrictions were employed.
Information sources and search
We searched Ovid MEDLINE from 1946, Ovid EMBASE
from 1980, Ovid PsycINFO from 1806, Ovid AMED from
1985, The Cochrane Library from 1898, CINAHL from
1981 and PEDRO from 1929, using subject headings and
text words (see online supplementary appendix 1). All
searches were up to date as of 25 November 2013. We
checked the reference lists of all included articles and
searched for unpublished and ongoing studies by corres-
pondence with authors and ﬁeld experts.
Study selection
To select publications eligible for this review, two authors
independently read all titles and abstracts in the records
retrieved by the searches. We obtained publications in
full text if the abstract was deemed eligible by at least one
review author. At least two authors independently read
the full text papers and selected studies according to the
inclusion criteria. Any disagreement between review
authors was resolved by discussion between the two
review authors or, if necessary, by involving all authors.
Data collection process
First, we listed all the identiﬁed case deﬁnitions for CFS/
ME. One author gathered information about citation
from ISI and Google Scholar to indicate the impact or
widespread of use, but we made no attempt to assess or
rank the quality of the case deﬁnitions at this stage.
To facilitate the validity assessment, we developed a
framework consisting of three different models.
Model A includes studies with independent application of
different case deﬁnitions on the same population (ﬁgure 1).
This model presents the interrelationship between sub-
populations identiﬁed by different case deﬁnitions.
Model B includes studies where patients diagnosed
with CFS/ME with one set of diagnostic criteria are diagnosed
sequentially with other case deﬁnitions assumed to have
increasing speciﬁcity (ﬁgure 2).
Model C includes surveys or cross-sectional studies esti-
mating the prevalence of CFS/ME by applying different
case deﬁnitions on different populations (ﬁgure 3).
These studies do not directly compare different case
deﬁnitions, but may be used for proxy evaluation,
similar to the strategy applied by Johnston et al.24 27
Two authors reviewed all potentially relevant valida-
tions studies, and categorised them according to model
A, B or C. Any disagreement between review authors at
this stage was resolved by reaching consensus in the
author group.
Risk of bias in individual studies
To differentiate between studies with higher and lower
risk of bias, we critically appraised all included validation
studies according to check lists: Studies comparing two
or more case deﬁnitions directly (ie, model A or B)
were appraised according to the QUADAS criteria28
(patient selection, index test, reference standard, ﬂow
and timing). For evaluation of prevalence studies (ie,
model C), we used an outline for assessment of external
and internal validity (11 items) of prevalence studies.29
Analysis
Participation in prevalence studies, surveys and question-
naires vary across the included studies. Non-response is
known to introduce bias, and methods to adjust for low
response rates are available.30 In studies affected by non-
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response, we have reported adjusted estimates whenever
applicable. If adjusted estimates were unavailable, we
have deﬁned the proportion as the number of cases
divided by the number of responders. We estimated
95% CIs for all proportions by using the
Clopper-Pearson exact binomial method. We used R
software V.3.0.0 and the rmeta package for statistical
computations and plotting.31 32
RESULTS
Study selection
Our systematic literature search identiﬁed 1660 unique
references, of which 56 articles fulﬁlled our inclusion
criteria (ﬁgure 4). Twenty articles present different case
deﬁnitions of CFS/ME for research or clinical prac-
tice20 22 23 33–49 (table 1). Furthermore, 38 studies were
classiﬁed as validation studies, contributing data of sufﬁ-
cient quality and consistency for evaluation of different
case deﬁnitions according to our inclusion criteria.
The degree to which the different case deﬁnitions had
been applied in research and clinical guidelines varied
widely, with CDC-1994/Fukuda et al39 as the most fre-
quently cited case deﬁnition of CFS/ME.
Thirteen of the 20 identiﬁed case deﬁnitions had
been assessed in one or more validation
studies.20 22 23 33 34 36 37 39–41 43 44 47 For seven case deﬁ-
nitions, no foundation for validation could be identiﬁed.
We did not identify any study which rigorously assessed
the reproducibility or feasibility of the different case
deﬁnitions.
Figure 1 Model A: evaluation
design with independent
application of several case
definitions on the same
background population (CFS,
chronic fatigue syndrome; ME,
myalgic encephalomyelitis).
Figure 2 Model B: evaluation design where different case
definitions with assumed increasing specificity are applied
sequentially on the same population (CFS, chronic fatigue
syndrome; ME, myalgic encephalomyelitis).
Figure 3 Model C: evaluation design with indirect
comparisons of prevalence estimates from several case
definitions applied on different populations (CFS, chronic
fatigue syndrome; ME, myalgic encephalomyelitis).
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Independent application of several case definitions on the
same population (model A)
Five studies (table 2) applied several case deﬁnitions on
the same population, but only one of these reported data
in a way that made it possible to compare the case deﬁni-
tions.50 51 Nacul et al50 used general practitioner (GP)
databases and questionnaires and identiﬁed 278 patients
with unexplained chronic fatigue (CF) conforming to one
or more of the case deﬁnition applied, that is, CDC-1994/
Fukuda et al,39 Canadian-200322 or ECD-2008.34 Most of
the patients who were positive according to the Canada
criteria (C+) were also positive using the Fukuda criteria
(F+). Forty-seven per cent of the Fukuda-positive patients
were also positive according to the Canada criteria.
Patients who were positive to the Canada and Fukuda
(C+/F+) reported a higher level of symptoms than
those who were (F+/C–). The authors did not identify
differences in the distribution of triggering factors.50
None of the other four studies in this group reported
data on the correlation between case deﬁnitions, patient
proﬁle and symptom burden. Application of CDC-1988/
Holmes case deﬁnition was consistently associated with
lower prevalence estimates than CDC-1994/Fukuda,
Oxford-1991 and Australian-1990 criteria across these
four studies. There was no consistent trend for the other
case deﬁnitions, but the studies were heterogeneous
regarding the application of different case deﬁnitions
and data collection (table 2). This observation suggests
that prevalence numbers obtained by different case deﬁ-
nitions should be controlled according to diagnostic pro-
cedure, cut-off points and reasons for exclusions before
concluding on differences.
Different case definitions with assumed increasing
specificity applied sequentially on the same
population (model B)
Twelve studies (table 3) sequentially applied different
case deﬁnitions on the same population. In these
studies, patients were screened by using an evaluation
standard. Subsequently, test-positive individuals were
screened with one or more comparators. Nine of the 12
studies applied CDC-1994/Fukuda as the evaluation
standard, and then tested Fukuda-positive patients with
CDC-1988/Holmes, Canadian-2003, ICC-2011, ME-2011,
Empirical-2006/Reeves, London-1990/Dowsett or
Neurasthenia case deﬁnitions.
We have taken the actual evaluation standard as a
point of departure, and calculated the proportion of
these patients still positive when applying other case
deﬁnitions. Since there are no test negatives for the case
deﬁnition used as point of departure, true sensitivities
or speciﬁcities cannot be calculated. Results from two of
the studies by Jason et al33 52 suggest that 40–70% of the
Fukuda-positive patients are also Canada positives (F+/C+).
One study52 concluded that there was less psychiatric
comorbidity and more physical functional impairment
in the subsample which was positive on both case deﬁni-
tions (F+/C+) than those who were negative according
to the Canada criteria (F+/C−). However, the other
study33 suggested a higher incidence of mental and cog-
nitive problems among Fukuda-positive patients who
were also Canada positive (F+/C+) as compared with
the remaining Fukuda-positive but Canada-negative
patients (F+/C−). In a separate publication,53 the same
Fukuda-positive patients as referred in Jason et al33 were
used to contrast ICC-2011. About 34% (95% CI 26% to
44%) of the Fukuda-positive patients were also ICC posi-
tives (F+/ICC+). Similar to the (F+/C+) subset, it was
found that (F+/ICC+) patients experienced more func-
tional impairments as well as more mental and cognitive
problems and higher psychiatric comorbidity than
(F+/ICC−) patients.
The comparisons presented in table 3 are associated
with high risk of bias as well as random errors, and the
results should be interpreted with great caution. For
example, two of the included studies reported similar
point prevalence according to CDC-1994/Fukuda (2.1%
and 2.6%) but reported very different estimates using
the Australian-1990 criteria (7.6% and 1.4%).54 55
Sometimes diagnoses were based on questionnaire
responses only, sometimes following detailed clinical
interviews and laboratory testing. There were also differ-
ences in the way similar case deﬁnitions were practiced
in the various studies, for example, some studies applied
a low threshold for exclusion of cases with psychiatric
comorbidity, while others did not.
Indirect comparisons of prevalence estimates
from several case definitions applied on different
populations (model C)
We identiﬁed 21 studies (table 4) presenting prevalence
estimates for CFS/ME (ﬁgure 3), in addition to the ﬁve
studies presenting prevalence estimates following the
application of multiple case deﬁnitions (table 2). Based
on these studies, we extracted 17 independent estimates
Figure 4 Flow chart summarising the selection process.
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of the prevalence following application of the
CDC-1994/Fukuda criteria (ﬁgure 5).
Our analysis suggests that the population prevalence
of CFS/ME according to the CDC-1994/Fukuda case
deﬁnition probably is less than 1% (range 0.1–6.4%;
median 1%), with higher prevalence among consecutive
GP attendants than from population studies. Prevalence
estimates seemed higher when patients were diagnosed
without a preceding medical examination. Prevalence
estimates of CFS/ME according to CDC-1988/Holmes
case deﬁnition seemed lower, with all the studies report-
ing prevalence estimates ranging from 0.0% to 0.3%
(median 0.05%).
Five studies54–58 reported CFS/ME prevalence esti-
mates according to the Oxford-1991 case deﬁnition.
These estimates ranged from 0.4% to 3.7% (median
1.5%). Four studies44 54–56 reported prevalence estimates
according to the Australian-1990 case deﬁnition ranging
from 0.04% to 7.6% (median 1.2%).
DISCUSSION
We identiﬁed 20 studies presenting different CFS/ME
case deﬁnitions, and 38 studies with data providing
access to comparison and evaluation of some of these.
Only a minority of existing case deﬁnitions had been
submitted to comparative evaluations. The validation
studies were methodologically weak and heterogeneous,
making it questionable to compare the case deﬁnitions.
The most cited case deﬁnition (CDC-1994/Fukuda
Table 1 Case definitions for CFS/ME
Case definitions
(chronologically)
Developed from other criteria or
definitions?
Institution and country of first
author
CITATIONS*
ISI/Google
Scholar
CDC-1988/Holmes et al20 Centers for Disease Control,
Atlanta, USA
1106/1542
ME-1988/Ramsey42 Royal Free Hospital, London, UK 6/51
London-1990/Dowsett et al37 Royal Free Hospital, London, UK 55/88
Australian-199044 The Prince Henry Hospital, Little
Bay, Australia
230/343
Postviral fatigue
syndrome-199043
Raigmore Hospital, Inverness, UK 14/28
Oxford-199140 University of Oxford, Oxford, UK 476/667
London ME-1994/National Task
Force Guidelines48
National Task Force, Bristol, UK No records
CDC-1994/Fukuda et al39 CDC-1988 Centers for Disease Control,
Atlanta, USA
1860/3006
Working case definition-199638 CDC-1988 Brigham and Women’s Hospital
Massachusetts, USA
78/138
CFS-199849 CDC-1994 Medical College of Wisconsin, USA 8/23
Canadian-200322 Royal College of Physicians and
Surgeons of Canada, Canada
69/233
Empirical CDC-2005/Reeves
et al63
CDC-1994 Centers for Disease Control and
Prevention, Atlanta, USA
73/154
Empirical-200741 DePaul University, Chicago, USA 5/14
Brighton Collaboration-200735 Centers for Disease Control and
Prevention, Atlanta, USA
1/5
NICE-2007 Guidelines46 National Institute for Health and
Clinical Excellence, London, UK
No records/23†
The Nightingale Definition
of ME-2007/Hyde45
The Nightingale Research
Foundation, Canada
No records/5
ECD-200834 Southampton, Hampshire, UK 2/4
Revised Canadian-201047 CDC-1994, Empirical CDC-2005,
Canadian-2003
DePaul University, Illinois, USA 8/18
ICC-201123 Canadian-2003 Independent, Canada 4/16
ME-201133 London-1990, ME-1988, The
Nightingale Definition of ME-2008
DePaul University, Illinois, USA 1/1
*Searched 23 May 2012.
†Summary of the NICE Guidelines in: diagnosis and management of chronic fatigue syndrome or myalgic encephalomyelitis
(or encephalopathy): summary of NICE guidance. BMJ 2007;335:446.
CFS, chronic fatigue syndrome; ICC, International Consensus Criteria; ME, myalgic encephalomyelitis; ECD, epidemiological CFS/ME
definition.
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et al39) is also the most extensively validated one,
whereas validation studies are few (Canadian-2003,22
ICC-201123) or missing (National Institute for Health
and Care Excellence (NICE)-200746) for recently pre-
sented and debated case deﬁnitions. We found no
empirical evidence supporting the hypothesis that some
case deﬁnitions more speciﬁcally identify patients with a
neuroimmunological condition.
Strengths and weaknesses of our study
The main strength of our study is the systematic
methods used to identify and appraise articles present-
ing case deﬁnitions of CFS/ME and studies potentially
useful to evaluate the case deﬁnitions. Furthermore, we
have used systematic and transparent approaches to
extract data from the validation studies, categorise the
studies according to three different models and to
analyse and compare the data.
The STARD initiative aims to improve the reporting
on studies of diagnostic accuracy, considering any
method for obtaining additional information on a
patient’s health status as a test.25 Owing to the lack of a
reference standard, we found this guideline less suitable
for review of articles evaluating case deﬁnitions for CFS/
ME. Still, issues such as study populations, test methods
and rationale, technical speciﬁcations for application of
the test, statistical methods for comparing measures of
accuracy and uncertainty, estimates of diagnostic accur-
acy, variability and clinical applicability25 are relevant
also for our analysis.
The validation studies we identiﬁed were small with
considerable methodological weaknesses and inconsist-
ent results. Only one study held a level of rigour where
independent application of several case deﬁnitions was
conducted on the same population (model A).50 Such a
study should ideally be based on a population sample
rather than a GP practice database, and should compare
a selection of currently applied and debated case
deﬁnitions, such as CDC-1994/Fukuda, Oxford-1991,
Canadian-2003 and NICE-2007.
The QUADAS criteria28 demonstrate that model B is
an evaluation strategy prone to several sources of bias.
First, the spectrum of patients subjected to the compara-
tor is selected and not representative of the population
receiving the test if it is used alone. Second, as compara-
tors were mostly applied subsequently to the evaluation
standard, the clinical evaluations were not independent.
The estimates from two of the Jason studies33 52 suggest a
comparable correspondence (40–70% of the F+ are also
C+) with the results presented by Nacul et al.50 Yet, model
B gives no or limited information regarding those who
screened negative in the ﬁrst place. We do not know
whether some of those might have had a positive diagno-
sis if screened with one of the other case deﬁnitions.
We are even more prone to bias when exploring the
consistency of different case deﬁnitions through indirect
comparisons of prevalence estimates obtained from dif-
ferent populations (model C), and great caution is
needed when such proxy comparisons are undertaken.
For example, two of the included studies reported
Table 2 Studies presenting prevalence estimates* by independent application of several case definitions on the same
population (model A)
First author, year, country Data collection Prevalence (95% CI) (%)
Nacul,50 2011, UK 609 possible cases electronically identified in databases
of 29 GP practices. 70 excluded after clinical revision
(explained fatigue), 135 refusals and 126 non-cases
ECD: 0.03 (0.02 to 0.04)
Canada: 0.10 (0.09 to 0.12)
Fukuda: 0.19 (0.17 to 0.21)
Bates,56 1993, USA 995 consecutive GP visitors invited—94% screened by a
questionnaire to detect major fatigue. Selected patients
further evaluated by questionnaires, physical
examinations and interviews
Holmes: 0.3 (0.1 to 0.9)
Oxford: 0.4 (0.1 to 1.1)
Australia: 1.1 (0.5 to 2.0)
Kawakami,57 1998, Japan All adults (n=508) in Town A, Kofu-city, were invited to
participate in this structured psychiatric diagnostic
interview survey. 137 (27%) completed the study
Holmes: 0.0 (0.0 to 2.7)
Fukuda: 1.5 (0.2 to 5.2)
Oxford: 1.5 (0.2 to 5.2)
Lindal,55 2002, Iceland Survey sent to 4000 randomly selected adult participants
—63% responded. Questionnaire included questions on
all items in the four case definitions. Diagnoses were set
electronically based on received responses. No medical
tests or examinations were undertaken
Holmes 0.0 (0.0 to 1.5)
Fukuda: 2.1 (1.6 to 2.8)
Oxford: 3.7 (3.2 to 4.6)
Australia: 7.6 (6.6 to 8.7)
Wessely,54 68 1997, UK 2363 patients followed in a cohort study—84%
completed. Fatigued participant subjected to detailed
questionnaires, interviews and laboratory testing.
Separate estimates reported for inclusion/exclusion of
psychiatric comorbidity
Holmes: 1.2 (0.5 to 1.8)
Australia: 1.4 (0.8 to 2.0)
Oxford: 2.2 (1.4 to 3.0)
Fukuda: 2.6 (1.7 to 3.4)
*Prevalence estimates were calculated with the number of responders in the denominator. The choice of denominator may have large
implications with regard to the subsequent prevalence estimate, particularly in studies with low response rate. Hence, depending on the actual
response rate, estimates presented for each study may be biased.
GP, general practitioner.
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Table 3 Conformity of prevalence estimates in studies where patients diagnosed with CFS/ME with one set of diagnostic criteria are diagnosed sequentially with other
case definitions (model B)
Study recruitment Case definitions Conformity* (95% CI) Symptom and burden profile
Brimacombe et al,69 USA
Fukuda-positive from register
Fukuda† (n=200)
Holmes (n=171)
1
0.85 (0.80 to 0.90)
(F+/H–) patients do not endorse infectious-type symptoms as often or to
the same degree of severity as (F+/H+) patients
Jason et al,70 USA
Fukuda-positive from register
Fukuda† (n=32)
Holmes (n=14)
1
0.44 (0.26 to 0.62)
(F+/H+) patients with more symptoms and functional impairment than
(F+/H–). No difference in psychological comorbidity
Jason et al,52 USA
Fukuda-positive from register
Fukuda† (n=32)
Canada (n=23)‡
1
0.63 (0.44 to 0.79)
C+ patients have less psychiatric comorbidity, more physical function
impairment, are more fatigued with more neurological symptoms than
(F+/C–) patients
Jason et al,33 USA
Fukuda-positive recruited from
many sources
Fukuda† (n=113)
Canada (n=57)
ME-2011 (n=27)
1
0.50 (0.41 to 0.60)
0.24 (0.16 to 0.33)
(F+/C+) patients had more functional impairments, and physical, mental
and cognitive problems than (F+/C–) patients. (F+/ME+) patients had
more functional impairments, and more severe physical and cognitive
symptoms than (F+/ME–) patients
Fluge et al,9 Norway
Fukuda-positive patients
recruited to trial
Fukuda† (n=30)
Canada (n=28)
1
0.93 (0.78 to 0.99)
Not reported
Jason et al,71 USA
Register
Fukuda† (n=24)
Reeves empirical
Canada
Of 24 F+ and 84 F-patients empirical
criteria and Canada identified 79 and
87% correctly
Canadia-2003 case definition appears to select more cardinal and central
features of the illness than Empirical CDC-2005/Reeves case definition
Jason et al,65 USA
Register
Fukuda† (n=27)
Reeves emp.
(n=41)§
1
1.00 (0.87 to 1.00)
Empirical CDC-2005/Reeves case definition led to misclassification of
major depressive disorder as CFS
Brown et al,53 USA
Fukuda-positive recruited from
many sources
Fukuda† (n=113)
ICC (n=39)
1
0.35 (0.26 to 0.44)
ICC+ patients with more functional impairments and physical, mental and
cognitive problems than (F+/ICC–) patients. The ICC+ patients also had
greater rates of psychiatric comorbidity
Jason et al,72 USA
Fukuda-positive from register
Fukuda† (n=32)
Dowsett (n=17)¶
1
0.44 (0.26 to 0.62)
D+ patients appear to be more symptomatic than (F+/D–) patients,
especially in the neurological and neuropsychiatric areas
White et al,60 UK
Oxford-positive patients
recruited to trial
Oxford† (n=641)
Fukuda (n=427)
London ME
(n=329)
1
0.67 (0.63 to 0.70)
0.51 (0.47 to 0.55)
Effect of CBT and GET similar regardless of diagnostic group affiliation
Wearden et al,73 UK
Oxford-positive patients
recruited to trial
Oxford† (n=296)
London ME
(n=92)
1
0.31 (0.26 to 0.37)
Not reported
Stubhaug et al,74 Norway
Neurasthenia-positive patients
recruited to trial
Neurasthenia†
(n=72)
Oxford (n=65)
Fukuda (n=29)
1
0.90 (0.81 to 0.96), 0.40 (0.29 to 0.53)
Not reported
*The proportion of cases relative to the evaluation standard.
†Evaluation standard.
‡Three of the 23 participants who tested positive according to the Canada criteria were negative according to Fukuda.
§14 of the 37 patients who tested positive according to Reeves were negative according to Fukuda (these 14 patients had a depression diagnosis).
¶Three of the 17 participants who tested positive according to Dowsett were negative according to Fukuda.
CBT, cognitive behavorial therapy; CFS, chronic fatigue syndrome; GET, graded exercise therapy; ICC, International Consensus Criteria; ME, myalgic encephalomyelitis.
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similar point prevalence according to CDC-1994/
Fukuda (2.1% and 2.6%), but reported very different
estimates following the application of the
Australian-1990 criteria (7.6% and 1.4%).54 55 This
inconsistency can be explained by major methodological
differences seen across the included studies. Our sample
includes studies in which a diagnosis of CFS/ME is
made on the basis of either questionnaire responses or
clinical interview. Previous studies suggest that patients
who receive a standardised questionnaire report consid-
erably more symptoms than when asked to report their
symptoms spontaneously.59 There are several other
sources to this between study heterogeneity, such as
recruitment strategy, response rate and strategies for
non-response adjustment. We were not able to identify
the most important one. However, Johnston et al27 per-
formed an interesting subgroup analysis in their
meta-analysis of 14 studies applying the CDC-1994/
Fukuda case deﬁnition, and found that the pooled
prevalence for self-reporting assessment was 3.28% (95%
CI 2.24% to 4.33%) compared with 0.76% (95% CI
0.23% to 1.29%) for clinical assessment. Prevalence was
lower in community samples (0.87%; 0.32% to 1.42%)
than in primary care samples (1.72%; 1.40% to 2.04%).
The prevalence estimates based on self-reports showed
high variability, while clinically assessed estimates were
more consistent, especially in the community samples.
The utility of case definitions and diagnoses
The utility of a diagnosis is linked to the potential
effects of being diagnosed (eg, beneﬁts and harms of
the patient’s role, access to treatment and insurance).
More importantly, a diagnosis is useful if it is linked to
valid information regarding prognosis or outcomes of
therapy. Reitsma et al26 suggest clinical test validation as
an alternative paradigm for evaluation of a diagnostic
test when an acceptable reference standard is missing.
Hence, primary studies and systematic reviews on prog-
nosis and therapy are alternative sources to evaluate the
usefulness of different case deﬁnitions of CFS/ME. We
have identiﬁed only one such publication, the PACE
trial.60 Here, participants were diagnosed according to
the Oxford-1991 criteria, Empirical criteria-2007/Reeves
and London ME-1994/National Task Force criteria, and
then randomised to either standard medical treatment,
graded exercise therapy, cognitive behaviour therapy or
pacing. The results showed that the effectiveness of the
treatments was similar across groups, irrespective of the
case deﬁnition which had been used. Fluge et al9
applied the CDC-1994/Fukuda and retrospectively
added the Canada criteria in their study on the effects
of rituximab in CFS with comparable results. In a recent
publication, Maes et al21 measured symptom severity,
selected biomarkers and postexertional malaise in 144
patients with CF, of whom 107 fulﬁlled the CDC-1994/
Table 4 Studies presenting prevalence estimates for CFS/ME from several case definitions applied on different populations
(model C)
First author, year, country Case definition Recruitment strategy
Bazelmans, 1999,75 The Netherlands As recognized by GP Questionnaire to all GPs, prevalence estimated to 0.11%
Lloyd, 1990,44 Australia Australian Recruited through GP’s covering 76 206 patients
Buchwald, 1995,76 USA CDC-1988/Holmes Postal survey to 4000 randomly selected participants
Gunn, 1993,77 USA CDC-1988/Holmes Recruited by contact with primary health care providers;
prevalence in the range 0.002–0.007%
Price, 1992,78 USA CDC-1988/Holmes Interview survey with 13 538 participants
Versluis, 1997,79 Netherlands CDC-1988/Holmes 23 000 patients in GP database
Bierl, 2004,80 USA CDC-1994/Fukuda Random digit-dialling survey with 7317 respondent
Cho, 2009,81 UK CDC-1994/Fukuda 2530 consecutive GP visitors
Cho, 2009,81 Brazil CDC-1994/Fukuda 3921 consecutive GP visitors
Evengård, 2005,82 Sweden CDC-1994/Fukuda Phone survey of 41 499 participants in a twin register
Hamagucchi, 2011,83 Japan CDC-1994/Fukuda 3000 random participants in a health check programme
Jason, 1999,84 USA CDC-1994/Fukuda Phone survey with 18 675 respondents
Kim, 2005,85 South Korea CDC-1994/Fukuda 1962 consecutive GP visitors
Njoku, 2007,86 Nigeria CDC-1994/Fukuda Interview survey with 1500 participants
Reeves, 2007,64 USA CDC-1994/empirical Phone survey with 10 837 responding households
Reyes, 2003,87 USA CDC-1994/Fukuda Phone survey with 33 997 responding households
Steele, 1998,88 USA CDC-1994/Fukuda Phone survey with 8004 responding households
van’t Leven, 2009,89 The Netherlands CDC-1994/Fukuda Postal survey to 22 500 randomly selected participants
Vincent, 2012,90 USA CDC-1994/Fukuda Retrospective medical record review in Olmsted County;
183 841 residents
Yiu, 2005,91 China CDC-1994/Fukuda Unknown
Lawrie, 1995,58 UK Oxford Postal survey to 1039 randomly selected participants
Ho-Yen, 1991,92 UK Post viral exhaustion
syndrome
Postal survey to 195 GPs; prevalence 0.13%
(0.12% to 0.15%)
CFS, chronic fatigue syndrome; GP, general practitioner; ME, myalgic encephalomyelitis.
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Fukuda criteria of CFS/ME. They claimed that CF, CFS
and ME are distinct categories, although stating that
patients group together in one continuum with no clear
boundaries between them.21 Such studies would be even
more useful if outcomes of speciﬁc treatment modes
had also been tested.
A study comparing the prognosis of different diagnos-
tic labels of fatigue found that patients with ME had the
worst prognosis while patients with postviral fatigue
syndrome had the best.61 This could mean that the
patients destined to the worst prognosis were labelled
with the ME diagnosis, or it might be explained as an
adverse effect of being labelled with ME. The authors
found no signiﬁcant difference in recorded fatigue
before the diagnosis of CFS and ME, and the data in
this retrospective study supported the hypothesis of the
labelling effect. Another study found that patients who
attributed their fatigue to ME were more fatigued and
Figure 5 Forest plot
summarising indirect comparisons
of prevalence estimates from
different case definitions
(model C). Studies presenting
point prevalence weighted for
non-response are asterisked (*).
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more handicapped in relation to home, work, social and
private leisure activities than patients who attributed
their fatigue to psychological or social factors.62
Broad or narrow case definitions?
Ideally, correspondence validity between test and target
should be 100% for sensitivity (the capacity to identify
patients in the target group) and speciﬁcity (the capacity
to rule out patients who do not belong to the target
group). More often, there is a trade-off between these
measures, depending on the purpose of diagnosis.
Emphasising sensitivity implies a risk of overdiagnosis,
which dilutes the actual diagnostic concept, while
emphasising speciﬁcity implies a risk of underdiagnosis,
dismissing patients who might beneﬁt from treatment.
Development of more exclusive case deﬁnitions for
CFS/ME has been proposed, claiming that existing case
deﬁnitions do not select homogenous sets of patients.23
More speciﬁcally, Oxford-1991, Fukuda-1994 and
NICE-2007 have been criticised, especially by patient
organisations, for undue overlap with psychopathology.
Proponents of recent case deﬁnitions, such as
Canada-2003 and ICC-2011, claim to achieve a narrow
selection of patients with ME conforming to a hypothe-
sised speciﬁc pathophysiology. Our review demonstrates,
however, that these case deﬁnitions do not necessarily
exclude patients with psychopathology.
A lesson could be learnt from Reeves, who tried to
elaborate the CDC1994/Fukuda deﬁnition and bring
methodological rigour into the diagnostic criteria by
scores from standardised and validated instruments.63
The Empirical-2006/Reeves case deﬁnition led to a
tenfold prevalence estimate as compared with the
CDC1994/Fukuda deﬁnition,64 probably due to mis-
classiﬁcation and inclusion of patients with major
depressive disorder.65 The purpose of rigour had not
been achieved, and the Empirical-2006/Reeves case def-
inition was never broadly implemented. According to
our review, it is uncertain whether a more homogenous
subset of patients can be achieved with the Canada-2003
and ICC-2011 case deﬁnitions. The authors of the latter
paper write: “Collectively, members have approximately
400 years of both clinical and teaching experience,
authored hundreds of peer-reviewed publications, diag-
nosed or treated approximately 50 000 patients with ME
and several members coauthored previous criteria.”23
This declaration is no validity criterion and provides no
guarantee that the case deﬁnition works according to
the intentions.
Case definitions for research or clinical practice?
Research requires uniform and reproducible criteria,
suitable for unambiguous deﬁnitions of the target popu-
lation. Another concern is to compare studies across time
and nations. These are arguments for an inclusive case
deﬁnition, preferably one which has been in use for a
while, and for which validation studies are available. In
CFS/ME research, the Oxford-1991 and CDC-1994/
Fukuda are the most frequently used case deﬁnitions.
Our review indicates that the former might be more
inclusive, with lower speciﬁcity than the latter, although
the impact of this is unclear. Proponents for more
restrictive case deﬁnitions dismiss ﬁndings from treat-
ment studies documenting effects of cognitive behav-
ioural treatment or graded exercise therapy for patients
diagnosed with the Oxford-1991 or CDC-1994/Fukuda
case deﬁnitions.66 Their claim is that for a more exclusive
selection of patients with ME, deﬁned according to spe-
ciﬁc hypothesised pathophysiology, the side effects of
these treatment modalities are hazardous. So far,
however, treatment studies based on the Canada-2003 or
ICC-2011 case deﬁnitions are not available.
Case deﬁnitions for clinical practice should be research
based, validated and manageable to provide a tool which
can relieve patient’s uncertainty, indicate the most
appropriate treatment and prevent adverse effects and
waste of healthcare resources of unnecessary treatment
and diagnostic procedures.67 They should be founded
on available knowledge regarding the mechanisms of
the actual condition, validated through credible and
transparent processes and presented in a format which
can be implemented in everyday practice. An argument
for more inclusive case deﬁnitions for CFS/ME would
be the issue of treatment, since existing evidence indi-
cates that side effects of cognitive behavioural treatment
or graded exercise therapy are negligible. For this
context, the CDC-1994/Fukuda case deﬁnition appears
suitable, with the NICE-2007 as a good candidate for val-
idation studies.
IMPLICATIONS FOR RESEARCH AND CLINICAL PRACTICE
On the basis of our review, we argue that development of
further case deﬁnitions of CFS/ME should be given low
priority, as long as causal explanations for the disease are
limited. It might still be useful to classify patients accord-
ing to severity and symptom patterns, aiming to identify
characteristics of patients that might predict differences
in prognosis or expected effects of therapy.
It is likely that all CFS/ME case deﬁnitions capture
conditions with different or multifactorial pathogenesis
and varying prognosis. The futile dichotomy of ‘organic’
versus ‘psychic’ disorder should be abandoned. Most
medical disorders have a complex aetiology.
Psychological treatments are often helpful also for clear-
cut somatic disorders. Unfortunately, patient groups and
researchers with vested interests in the belief that ME is
a distinct somatic disease seem unwilling to leave the
position that ME is an organic disease only. This position
has damaged the research and practice for patients suf-
fering from CFS/ME.
CONCLUSIONS
Our review provided no evidence that any of the case
deﬁnitions identify patients with speciﬁc or ‘organic
only’ disease aetiology. Priority should be given to
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further development and testing of promising treatment
options for patients with CFS/ME. Classiﬁcation of
patients according to severity and symptom patterns,
aiming to identify characteristics of patients that might
predict differences in prognosis or expected effects of
therapy, might be useful. Development of further case
deﬁnitions of CFS/ME should be given low priority.
Consistency in research can be achieved by application
of diagnostic criteria which have been systematically eval-
uated and compared with other case deﬁnitions.
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